1. Introduction {#sec1-brainsci-10-00525}
===============

Bipolar disorder (BP) is a common, chronic, and highly morbid illness characterized by hypomanic/manic and depressive episodes, which often runs a relapsing and remitting course, affecting 2--3% of the general population worldwide \[[@B1-brainsci-10-00525],[@B2-brainsci-10-00525]\]. Usually, BP onset occurs during adolescence or early adult years (mean age \~20 years old), that is, before or during the most productive period of adulthood \[[@B3-brainsci-10-00525],[@B4-brainsci-10-00525]\].

Although it is largely recognized that an early intervention improves the prognosis and decreases the burden of the disease, there is still an important delay between illness onset and diagnosis, with an average delay of 5--10 years \[[@B5-brainsci-10-00525],[@B6-brainsci-10-00525]\]. One of the major diagnostic difficulties is to differentiate BP from unipolar depression. This difficulty is due to several factors, such as: (1) first mood episode is depressive in half of the patients; (2) bipolar patients spend more time with depressive symptoms than with manic symptoms; (3) the search for help is more frequent in depressive episodes; (4) hypomanic episodes or mixed symptoms often go unrecognized \[[@B5-brainsci-10-00525],[@B6-brainsci-10-00525],[@B7-brainsci-10-00525],[@B8-brainsci-10-00525],[@B9-brainsci-10-00525]\]. Sometimes patients with bipolar disorder may also be misdiagnosed with other psychiatric disorders, such as psychotic or substance use disorders, whenever psychotic symptoms or substance misuse prevail and mask affective symptoms \[[@B10-brainsci-10-00525],[@B11-brainsci-10-00525]\]. Additionally, patients with an onset of disease before 18 years old are more likely to have longer delays in diagnosis and first intervention, due to a greater difficulty for the clinicians to identify less severe mood variations during childhood and adolescence, as well as the greater frequency of a depressive onset in those patients \[[@B2-brainsci-10-00525],[@B3-brainsci-10-00525],[@B5-brainsci-10-00525]\]. As both longer periods of untreated illness and an early onset have been related with poorer prognosis of the disease, the diagnostic delay in this subgroup of patients is of particular importance \[[@B3-brainsci-10-00525],[@B4-brainsci-10-00525],[@B12-brainsci-10-00525]\].

Prevention and early intervention are major goals of modern medicine. In this context, clinical staging models for mental illness, including BP, have been created. These staging models, based on the hypothesis of neuroprogression in mental disorders, establish a basis for therapeutic intervention strategies in the different illness stages, including the early ones \[[@B13-brainsci-10-00525]\]. Evidence suggests the existence of a period of subthreshold and nonspecific symptoms (prodrome) before the full manifestation of the illness \[[@B14-brainsci-10-00525]\]. The most replicated finding to date has been the presence of subthreshold manic symptoms prior to the first full-blown manic episode \[[@B15-brainsci-10-00525]\]. A recent meta-analysis, of early manifestations of BP in youth, however, found a variety of prodromal symptoms in this population, the most frequent being increased energy, diminished ability to think, indecision, pressured speech, talkativeness, elated mood, academic or work difficulties, insomnia, depressed mood, and increased goal-directed activities \[[@B16-brainsci-10-00525]\]. Hence, they warn that the prodromal period appears to be heterogeneous and thus highlight the need of an individualized approach when assessing prodromes of bipolar disorder. Different clinical and sociodemographic factors also have been pointed out as predictors of a higher risk of progression to BP in depressed patients, the most consistent being a family history of BP, earlier age at onset, presence of psychotic symptoms, atypical depressive symptoms, and subthreshold manic symptoms \[[@B7-brainsci-10-00525],[@B17-brainsci-10-00525]\].

Although many risk factors for conversion to BP have been identified, there is a need to develop tools that are easy to access and use, such as risk calculators, that allow clinicians to quantify the individual risk of conversion to BP and support them in choosing more specific therapeutic approaches \[[@B13-brainsci-10-00525]\].

Multiple models of risk calculation have been developed in different medical areas, such as cardiovascular diseases and cancer, which allowed the identification of risk populations and the implementation of screening programs and early intervention measures \[[@B2-brainsci-10-00525]\]. Risk calculators are clinical instruments developed based on the data available for a particular disease, identifying the ideal set of clinical factors that makes it possible to estimate the likelihood that an individual will develop a specific condition in the future. \[[@B18-brainsci-10-00525]\] They make it possible to derive the risk forecast for an individual, using a multivariate model based on the disease's progression in a large sample of patients. Through imputation, calculators can accommodate incomplete information about risk indicators, complementing the traditional clinical assessment. Nonetheless, they become more reliable, with a narrower range of certainty and the more complete the information available in a given case. \[[@B19-brainsci-10-00525]\] Currently, predictive models must accurately reflect existing patterns in the underlying data, being valid when the data are comparable and replicable in different samples. Several factors can contribute to a low predictive robustness and replicability of a model, such as a high frequency of missing data or a small set of data in the sample used for the development of the model \[[@B20-brainsci-10-00525]\].

Despite the multiple existing studies on risk factors, calculation models in psychiatry are still scarce, the most commonly studied being those evaluating the risk for developing psychosis or schizophrenia in prodromal samples \[[@B21-brainsci-10-00525],[@B22-brainsci-10-00525],[@B23-brainsci-10-00525]\].

This study aims to review all the risk calculators developed for BP, namely, what variables they evaluated, their predictive value, and their main limitations. We sought as well to provide a critical analysis of the current state of knowledge in the area, as well as to establish starting points for the elaboration of other models with applicability in clinical practice.

2. Materials and Methods {#sec2-brainsci-10-00525}
========================

We performed a systematic review according to Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines \[[@B24-brainsci-10-00525]\].

Original studies on risk calculators for conversion to BP in at-risk populations, using a set of clinical variables and/or biomarkers available on clinical practice, written in English, Portuguese or Spanish languages, and published in a scholarly peer-reviewed journal were eligible for this review, with no year or country restriction. We identified the studies by searching relevant papers via *PubMed/MEDLINE* (<http://www.ncbi.nlm.nih.gov/pubmed>) and *Embase* (<https://www.embase.com>) using the following keywords: ("bipolar disorder" OR "mania" OR "bipolar depression") AND ("prediction" OR "risk prediction" OR "prediction models" OR "predictive model" OR "risk score" OR "risk calculator"). The last article search was on April 2020.

Each study's title and abstract were screened for eligibility by the first and second authors; subsequently, full texts of all potentially relevant studies were revised and examined for eligibility. We analyzed the included studies and extracted information about: (a) country in which data were collected, (b) participants' characteristics, (c) number of subjects included, (d) follow-up time, (e) type of variables included in the risk calculator, (f) main results, (g) main conclusions, (h) limitations, and (i) risk of bias.

The quality of the studies selected for review was evaluated with the *Newcastle-Ottawa Quality Assessment Form for Cohort Studies* that assesses selection, comparability and outcome/exposure domains \[[@B25-brainsci-10-00525]\].

The quality of the risk models' development and validation was assessed in accordance with the recommendations of the *Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) Initiative* \[[@B26-brainsci-10-00525]\].

3. Results {#sec3-brainsci-10-00525}
==========

A total of 1339 articles were initially screened by title and abstract, with 28 selected for full-text reading. After the full-text review, only three studies met the eligibility criteria for inclusion in this systematic review. One study was from China \[[@B27-brainsci-10-00525]\] and the other two were from the United States of America \[[@B18-brainsci-10-00525],[@B28-brainsci-10-00525]\]. In [Figure 1](#brainsci-10-00525-f001){ref-type="fig"}, the PRISMA flow diagram is presented, providing more detailed information regarding the selection process.

Gan et al. developed a risk calculator for conversion from major depressive episode to BP from a sample of patients diagnosed with a depressive episode and followed for one year in an outpatient clinic \[[@B27-brainsci-10-00525]\]. This calculator uses six clinical variables: age of onset, maximum duration of depressive episodes, somatalgia, hypersomnia, diurnal variation of mood, and irritability. In a one-year follow-up of 344 patients diagnosed with depressive episode, those variables were the ones with higher predictive value and therefore included in their instrument, with an AUC of 0.85, a sensitivity of 75%, and a specificity of 83%.

The study of Hafeman et al. included offspring of patients with BP I or II recruited from The Pittsburgh Bipolar Offspring Study and elaborated a risk calculator for assessing the probability of developing new-onset bipolar spectrum disorders (BPSD) \[[@B28-brainsci-10-00525]\]. Their model uses seven clinical variables: mania, depression, anxiety, emotional lability, functioning, age at visit, and parental age of BP onset. Four different risk score cutoffs were established and the positive predictive value, sensitivity, and specificity for each one were presented (as shown in [Table 1](#brainsci-10-00525-t001){ref-type="table"}).

In another study from the same group, Birmaher et al. recruited youths with BP Not-Otherwise-Specified (BP-NOS) from the Course and Outcome of Bipolar Youth (COBY) study and developed a risk calculator of conversion to BP-I or II \[[@B18-brainsci-10-00525]\]. This model is based on ten demographic and clinical variables (mania, depression, anxiety, emotional lability, functioning, duration of illness, age, race, gender, and family history), with an AUC of 0.71. The study was externally validated in a sample from The Pittsburgh Bipolar Offspring Study, with an even stronger discrimination (AUC = 0.75).

All data regarding the variables included in each calculator, their predictive value, and limitations are shown in [Table 1](#brainsci-10-00525-t001){ref-type="table"}.

[Table 2](#brainsci-10-00525-t002){ref-type="table"} shows the studies' quality assessment based on the Newcastle-Ottawa Quality Assessment Form for Cohort Studies. This instrument assesses the quality of non-randomized studies with a star system evaluating three perspectives: (1) selection of the study groups, (2) comparability of the groups, and (3) the outcome of interest. All studies were evaluated as being of good quality, although all three present a risk of significant selection bias, since the sample is obtained from selected groups.

[Table 3](#brainsci-10-00525-t003){ref-type="table"} presents the quality assessment according with TRIPOD initiative recommendations. According to these recommendations, generally all models have good reporting quality, although none of them explains clearly how to use the risk calculator. The study by Birmaher et al. is the only one which was externally validated \[[@B18-brainsci-10-00525]\].

4. Discussion {#sec4-brainsci-10-00525}
=============

Risk prediction models are useful tools to guide the clinicians in decision making, regarding the risk to develop a certain medical condition and its individual management \[[@B29-brainsci-10-00525]\]. Risk calculators estimate the probability of an individual to develop a particular outcome based on different predictors, such as demographic variables, clinical evaluation, and complementary diagnostic exam results \[[@B30-brainsci-10-00525]\]. In the last decades, risk prediction models have been proposed in different areas of medical knowledge. The Framingham Study on cardiovascular disorders is, probably, the best-known example of risk prediction models in medicine, predicting the cardiovascular risk \[[@B28-brainsci-10-00525],[@B29-brainsci-10-00525]\].

In psychiatry, the development of risk prediction models becomes more challenging, due to the absence of easily quantifiable diagnostic parameters, but, at the same time, its potential value is even higher than in other areas of medicine. Precision psychiatry should integrate different sources of information about the individual, such as biographical, clinical, and biological data \[[@B31-brainsci-10-00525]\]. The fact that there is still much to understand about the etiopathological mechanisms and the lack of reliable biomarkers for psychiatric disorders contribute to the paucity of clinical risk prediction models in mental illness \[[@B32-brainsci-10-00525]\]. Consequently, psychiatry has traditionally focused more on the development of treatments that minimize the consequences of the disease than on prevention and early intervention \[[@B33-brainsci-10-00525]\].

Most studies of risk factors for bipolar disorder focus on examining the risk in an entire group rather than quantifying an individual's risk of having that disorder, which is essential to advance through personalized monitoring and treatment strategies \[[@B22-brainsci-10-00525]\]. In that regard, analyzing risk prediction models and building risk calculators are essential initial steps toward advancing individualized treatment and eventually, targeted prevention strategies to reduce an individual's risk \[[@B34-brainsci-10-00525]\].

Several studies have identified multiple risk factors for the development of BP, such as family history or atypical depressive symptoms \[[@B33-brainsci-10-00525]\]. In addition, the growing knowledge about the pathogenesis and pathophysiology of the disease over the past few years has allowed the identification of potential biomarkers that may become important assistants in the differential diagnosis \[[@B6-brainsci-10-00525]\].

Some biomarkers have been found to be differentially altered in BP patients and healthy controls, like high-sensitivity C-reactive protein, interleukin-6, brain derived neurotrophic factor or tumor necrosis factor (TNF)-α, and, more recently, serum uric acid levels, have proven useful as a predictor of bipolarity in individuals with a major depressive episode \[[@B31-brainsci-10-00525],[@B35-brainsci-10-00525],[@B36-brainsci-10-00525],[@B37-brainsci-10-00525]\].

Despite the increasing knowledge about risk factors and biomarkers in BP, findings are sometimes contradictory, which limits their usefulness in clinical practice. Therefore, it is important to systematize information and create accessible tools, easy to use, on daily basis, in a clinical setting.

In this study, we reviewed the existing risk calculators of conversion for BP. As shown in the results section, although there are numerous studies that point out various risk factors for the development of bipolar disorder, only three risk calculators were found. Therefore, these results show the lack of risk quantification models in mental illness.

Despite recent advances in the field of genetics, peripheral, and neuroimaging markers, all three studies reviewed have calculators based on sociodemographic and clinical variables \[[@B31-brainsci-10-00525],[@B34-brainsci-10-00525],[@B35-brainsci-10-00525],[@B36-brainsci-10-00525],[@B37-brainsci-10-00525],[@B38-brainsci-10-00525]\]. Despite this, all the risk calculators presented predictive values that are quite promising and comparable to those of risk calculators in other areas of medicine, such as cardiovascular diseases \[[@B18-brainsci-10-00525],[@B27-brainsci-10-00525],[@B28-brainsci-10-00525],[@B29-brainsci-10-00525]\].

Although it lacks replication and external validation, the study by Gan et al. shows good results, with an AUC of 0.85, a sensitivity of 75%, and a specificity of 83%. In addition, the lack of information regarding the questionnaire used to assess the variables, which was developed by the researchers, is a major limitation \[[@B27-brainsci-10-00525]\].

The studies of Hafeman et al. and Birmaher et al. have the advantage of establishing different risk score cutoffs, presenting the positive predictive value, sensitivity, and specificity for each one, which can be useful in stratifying risk at different levels and the consequent adaptation of early intervention strategies for each at-risk individual. However, these two calculators have been developed in BP at-risk populations, and it is unknown how they would perform in youth without a family history or with BP-NOS. The study by Birmaher et al. was the only one that was externally validated in a sample from The Pittsburgh Bipolar Offspring Study, with an even stronger discrimination than the original population.

Despite their good results, the risk calculators reviewed here still need to be replicated and externally validated in different populations, since they were all developed in selected populations and are potentially not representative of the population that we usually deal with in clinical practice, due to the risk of selection bias \[[@B35-brainsci-10-00525],[@B39-brainsci-10-00525]\]. In fact, although calculators give the clinician an estimate of individuals with a higher or lower risk of developing BP, their implementation should always be complemented with a detailed clinical assessment. The risk calculators may be useful as a screening in populations considered at risk for the development of BP, allowing the identification of individuals who need closer monitoring in order to reduce the diagnostic delay and allow an early intervention. However, these tools cannot be used in isolation, since the individual pattern of symptoms, as well as their temporal evolution, are essential for proper and truly personalized diagnosis and intervention \[[@B31-brainsci-10-00525]\].

One limitation of our study was the exclusion of articles published in languages other than English, Portuguese, and Spanish. Moreover, due to the scarce research on this topic and the heterogeneity in study design, we were not able to conduct a meta-analysis that would have been useful to provide important information regarding the predictive power of the existing models.

5. Conclusions {#sec5-brainsci-10-00525}
==============

In the future, it is possible that new risk calculators will include not only sociodemographic and clinical variables, but also some biomarkers, which may contribute to an even greater predictive value. Future research should also focus on the replication and validation of risk prediction models, and in making them useful and easily applicable in clinical practice.
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brainsci-10-00525-t001_Table 1

###### 

Summary of the articles on developing risk prediction models for bipolar disorder (BP).

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Article                  Sample Characteristics                                                           Variables Included in the Model            Variables Assessment                                                               Risk Prediction Statistics   Classification Statistics   Main Conclusions/Outcomes                                                                                                                                                                                                                                                                          Limitations
  ------------------------ -------------------------------------------------------------------------------- ------------------------------------------ ---------------------------------------------------------------------------------- ---------------------------- --------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gan et al. (2011)        N = 344 patients with major depressive episodes;\                                Age at first onset\                        Questionnaire designed by the researchers                                          SRD = 0.70\                  PPV = 0.87\                 The model based on six clinical characteristics robustly predict the transition from major depressive episodes to BP.                                                                                                                                                                              Short follow-up period;\
                           268 completing 1-year follow-up\                                                 Maximum duration of depressive episodes\                                                                                      AUC = 0.85                   NPV = 0.67\                                                                                                                                                                                                                                                                                                                    possibility of selection bias;\
                           Proportion of the outcome = 63% (n = 169)                                        Somatalgia\                                                                                                                                                SEN = 75%\                                                                                                                                                                                                                                                                                                                     the anti-depressant treatment was not assessed;\
                                                                                                            Hypersomnia\                                                                                                                                               SPE = 83%                                                                                                                                                                                                                                                                                                                      without external validation.
                                                                                                            Diurnal variation of mood\                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                                                                            Irritability                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Hafeman et al. (2017)    N = 412 Bipolar at-risk (offspring of BP I and II) completing 5-year follow-up   Mania\                                     1\. Modified K-SADS Mania Rating Scale (KMRS)\                                     AUC = 0.76                   Risk Score Cutoff 0.5:\     A model based on anxiety, manic symptoms, depressive symptoms, mood lability, poor general psychosocial functioning, and earlier parental age at onset individually and collectively assessed the probability of new-onset BPSD within the next 5 years in a population at familial risk for BP.   Few youths were diagnosed with BP I or II;\
                                                                                                            Depression\                                2. Depression items from K-SADS--Present Version (KDRS)-Modified\                                               PPV = 0.15\                                                                                                                                                                                                                                                                                                                    Follow-up visits scheduled every 2 years without external validation.
                                                                                                            Anxiety\                                   3. SCARED-Screen for Child Anxiety Related Emotional Disorders (child reported)\                                SEN = 0.82\                                                                                                                                                                                                                                                                                                                    
                                                                                                            Emotional lability\                        4. CALS-Children's Affective Lability Scale (child reported)\                                                   SPE = 0.49\                                                                                                                                                                                                                                                                                                                    
                                                                                                            Functioning\                               5. CGAS-Children's Global Assessment Scale                                                                      Risk Score Cutoff 0.10:\                                                                                                                                                                                                                                                                                                       
                                                                                                            Offspring age at visit\                                                                                                                                    PPV = 0.22\                                                                                                                                                                                                                                                                                                                    
                                                                                                            Parental age at mood disorder onset                                                                                                                        SEN = 0.53\                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                       SPE = 0.80\                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                       Risk Score Cutoff 0.15:\                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                       PPV = 0.30\                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                       SEN = 0.37\                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                       SPE = 0.91\                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                       Risk Score Cutoff 0.20:\                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                       PPV = 0.32\                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                       SEN = 0.21\                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                       SPE = 0.95                                                                                                                                                                                                                                                                                                                     

  Birmaher et al. (2018)   N = 140 BP-NOS; 120 completing 5-year follow-up                                  Mania\                                     1\. Modified KMRS (K-SADS Mania Rating Scale)\                                     AUC = 0.71                   Risk Score Cutoff 0.20:\    A model based on family history of hypo/mania and elevated levels of manic, mood lability, and anxiety symptoms can predict the conversion risk from BP-NOS to BP I or II in patients ages 6--17 years old.\                                                                                       Majority of participants were Caucasian recruited from clinical settings; the presence of factors associated with high-risk for conversion are not stable and may change over time
                                                                                                            Depression\                                2. Modified KDRS (K-SADS--Present Version)\                                                                     PPV = 0.46\                 Results were externally validated in a sample recruited from the community (BIOS) with an even stronger discrimination (75%).\                                                                                                                                                                     
                                                                                                            Anxiety\                                   3. SCARED-Screen for Child Anxiety Related Emotional Disorders (child reported)\                                NPV = 0.85\                 If the conversion did not occur within four years of the initial BP-NOS diagnosis, the risk dropped considerably.                                                                                                                                                                                  
                                                                                                            Emotional lability\                        4. CALS-Children's Affective Lability Scale (child reported)\                                                   SEN = 0.86\                                                                                                                                                                                                                                                                                                                    
                                                                                                            Functioning\                               5. CGAS-Children's Global Assessment Scale                                                                      SPE = 0.44\                                                                                                                                                                                                                                                                                                                    
                                                                                                            Duration of Bipolar Illness (Years)\                                                                                                                       Risk Score Cutoff 0.25:\                                                                                                                                                                                                                                                                                                       
                                                                                                            Child's Age\                                                                                                                                               PPV = 0.52\                                                                                                                                                                                                                                                                                                                    
                                                                                                            Race\                                                                                                                                                      NPV = 0.81\                                                                                                                                                                                                                                                                                                                    
                                                                                                            Family History of Mania\                                                                                                                                   SEN = 0.75\                                                                                                                                                                                                                                                                                                                    
                                                                                                            Gender                                                                                                                                                     SPE = 0.61\                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                       Risk Score Cutoff 0.30:\                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                       PPV = 0.56\                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                       NPV = 0.77\                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                       SEN = 0.62\                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                       SPE = 0.72\                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                       Risk Score Cutoff 0.35:\                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                       PPV = 0.60\                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                       NPV = 0.73\                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                       SEN = 0.47\                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                       SPE = 0.82\                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                       Risk Score Cutoff 0.40:\                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                       PPV = 0.65\                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                       NPV = 0.71\                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                       SEN = 0.36\                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                       SPE = 0.89                                                                                                                                                                                                                                                                                                                     
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AUC = area under the curve; BIOS = Pittsburgh Bipolar Offspring Study; BP: Bipolar Disorder; BPSD: bipolar spectrum disorder; BP-NOS: Bipolar Disorder Not-Otherwise-Specified; NPV = negative predictive value; PPV = positive predictive value; SEN = sensitivity; SPE = specificity; SRD = success rate difference.

brainsci-10-00525-t002_Table 2

###### 

Quality Assessment based on Newcastle-Ottawa Quality Assessment Form for Cohort Studies.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                       Gan et al.                                                                          Hafeman et al.                                                              Birmaher et al.
  ------------------------------------------------------------------------------ ------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------------------------------
  **SELECTION**                                                                  1\. Representativeness of the exposed cohort                                          Selected group                                                                      Selected group                                                              Selected group

  2\. Selection of the non-exposed cohort                                        Same community as the exposed cohort (⁕)                                              Same community as the exposed cohort (⁕)                                            Same community as the exposed cohort (⁕)                                    

  3\. Ascertainment of exposure                                                  Structured interview (⁕)                                                              Structured interview (⁕)                                                            Structured interview (⁕)                                                    

  4\. Demonstration that outcome of interest was not present at start of study   Yes (⁕)                                                                               Yes (⁕)                                                                             Yes (⁕)                                                                     

  **COMPARABILITY**                                                              1\. Comparability of cohorts based on design or analysis controlled for confounders   Study controls for age and other different sociodemographic and clinical factors\   Study controls for other different sociodemographic and clinical factors\   Study controls for other different sociodemographic and clinical factors\
                                                                                                                                                                       (⁕⁕)                                                                                (⁕)                                                                         (⁕)

  **OUTCOME**                                                                    1\. Assessment of outcome                                                             Independent blind assessment (⁕)                                                    No description                                                              Independent blind assessment (⁕)

  2\. Follow-up long enough for outcomes to occur\                               No\                                                                                   Yes (⁕)\                                                                            Yes (⁕)\                                                                    
  (Indicate the median duration)                                                 (1 year follow-up)                                                                    (median of 9.5 years)                                                               (median of 11.5 years)                                                      

  3\. Adequacy of follow-up of cohorts                                           Subjects lost to follow up unlikely to introduce bias (⁕)                             No statement                                                                        No statement                                                                

                                                                                 **RESULT**                                                                            **Good Quality**                                                                    **Good Quality**                                                            **Good Quality**
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

brainsci-10-00525-t003_Table 3

###### 

Quality assessment of the calculators according to the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) checklist.

  Section/Topic                  Item                                                                                                                                                                                                 Checklist Item                                                                                                                                                                                          Gan et al.   Hafeman et al.   Birmaher et al.
  ------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------ ---------------- -----------------
  **Title and abstract**                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Title                          1                                                                                                                                                                                                    Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.                                                            ✓            ✓                ✓
  Abstract                       2                                                                                                                                                                                                    Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.                                                 ✓            ✓                ✓
  **Introduction**                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Background and objectives      3a                                                                                                                                                                                                   Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.        ✓            ✓                ✓
  3b                             Specify the objectives, including whether the study describes the development or validation of the model or both.                                                                                    ✓                                                                                                                                                                                                       ✓            ✓                
  **Methods**                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Source of data                 4a                                                                                                                                                                                                   Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.                                 ✓            ✓                ✓
  4b                             Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.                                                                                       ✓                                                                                                                                                                                                       ✓            ✓                
  Participants                   5a                                                                                                                                                                                                   Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centers.                                                            ✓            ✓                ✓
  5b                             Describe eligibility criteria for participants.                                                                                                                                                      ✓                                                                                                                                                                                                       ✓            ✓                
  5c                             Give details of treatments received, if relevant.                                                                                                                                                    n/a                                                                                                                                                                                                     n/a          n/a              
  Outcome                        6a                                                                                                                                                                                                   Clearly define the outcome that is predicted by the prediction model, including how and when assessed.                                                                                                  ✓            ✓                ✓
  6b                             Report any actions to blind assessment of the outcome to be predicted.                                                                                                                               ✓                                                                                                                                                                                                       ✓            ✓                
  Predictors                     7a                                                                                                                                                                                                   Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.                                                           ✓            ✓                ✓
  7b                             Report any actions to blind assessment of predictors for the outcome and other predictors.                                                                                                           ✓                                                                                                                                                                                                       ✓            ✓                
  Sample size                    8                                                                                                                                                                                                    Explain how the study size was arrived at.                                                                                                                                                              ✓            ✓                ✓
  Missing data                   9                                                                                                                                                                                                    Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.                                                    ✓            ✓                ✓
  Statistical analysis methods   10a                                                                                                                                                                                                  Describe how predictors were handled in the analyses                                                                                                                                                    ✓            ✓                ✓
  10b                            Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation                                                                         ✓                                                                                                                                                                                                       ✓            ✓                
  10c                            For validation, describe how the predictions were calculated.                                                                                                                                        n/a                                                                                                                                                                                                     n/a          ✓                
  10d                            Specify all measures used to assess model performance and, if relevant, to compare multiple models.                                                                                                  ✓                                                                                                                                                                                                       ✓            ✓                
  10e                            Describe any model updating (e.g., recalibration) arising from the validation, if done.                                                                                                              n/a                                                                                                                                                                                                     n/a          n/a              
  Risk groups                    11                                                                                                                                                                                                   Provide details on how risk groups were created, if done.                                                                                                                                               n/a          ✓                ✓
  Development vs. validation     12                                                                                                                                                                                                   For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.                                                                           n/a          n/a              ✓
  **Results**                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Participants                   13a                                                                                                                                                                                                  Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.   ✓            ✓                ✓
  13b                            Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.   ✓                                                                                                                                                                                                       ✓            ✓                
  13c                            For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).                                                       n/a                                                                                                                                                                                                     n/a          ✓                
  Model development              14a                                                                                                                                                                                                  Specify the number of participants and outcome events in each analysis                                                                                                                                  ✓            ✓                ✓
  14b                            If done, report the unadjusted association between each candidate predictor and outcome                                                                                                              ✓                                                                                                                                                                                                       ✓            ✓                
  Model specification            15a                                                                                                                                                                                                  Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point)                              ✓            ✓                ✓
  15b                            Explain how to use the prediction model                                                                                                                                                              ✓                                                                                                                                                                                                       ✓            ✓                
  Model performance              16                                                                                                                                                                                                   Report performance measures (with CIs) for the prediction model                                                                                                                                         ✓            ✓                ✓
  Model updating                 17                                                                                                                                                                                                   If done, report the results from any model updating (i.e., model specification, model performance)                                                                                                      n/a          n/a              n/a
  **Discussion**                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Limitations                    18                                                                                                                                                                                                   Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).                                                                                        ✓            ✓                ✓
  Interpretation                 19a                                                                                                                                                                                                  For validation, discuss the results with reference to performance in the development data, and any other validation data.                                                                               n/a          n/a              ✓
  19b                            Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence.                                                       ✓                                                                                                                                                                                                       ✓            ✓                
  Implications                   20                                                                                                                                                                                                   Discuss the potential clinical use of the model and implications for future research.                                                                                                                   ✓            ✓                ✓
  **Other information**                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Supplementary information      21                                                                                                                                                                                                   Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.                                                                           ✓            ✓                ✓
  Funding                        22                                                                                                                                                                                                   Give the source of funding and the role of the funders for the present study.                                                                                                                           ✓            ✓                ✓
